VEGF-A and Ang-2 drive retinal vascular disease together1-5

ang2

Start with the power of dual pathway inhibition1,6,7

VABYSMO is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease1,6-9

Fc region: Fragment crystallisable region is the tail region of the antibody

References

  1. Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.
  2. Augustin AJ, et al. Clin Ophthalmol. 2009;3:175–82.
  3.  Heier JS, et al. Retina. 2021;41:1–19.
  4.  Joussen AM, et al. Eye (Lond). 2021;35:1305–16.
  5.  Larsen HO, et al. Ophth Ther. 2023;12:2253–64.
  6. Heier JS, et al. Lancet. 2022;399:729–40.
  7.  Wykoff CC, et al. Lancet. 2022;399:741–55.
  8.  VABYSMO®. SmPC https://go.roche.com/Vabysmo_SmPC Accessed May 2024
  9.  VABYSMO®. Prescribing Information. https://www.gene.com/download/pdf/vabysmo_prescribing.pdf Accessed May 2024